Effect of MD1003 in Progressive Multiple Sclerosis (SPI2)

About this study

Last updated on

This study is for people with:Multiple Sclerosis
Intervention being studied:MD1003 100mg capsule, PLACEBO (drug)
Purpose:
Treatment
A study testing a potential treatment for a disease or condition.
Sponsored by:MedDay Pharmaceuticals SA
Number of participants:600 participants
Unique study IDNCT02936037

How to apply

Find a study site convenient for you below, then email yourself the contact details and next steps.

Choose a site

Participation requirements

Open toboth females and males
Open to people aged18 to 65 years old

There are 116 locations for this study